BriaCell Therapeutics Corp
BriaCell Therapeutics Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BriaCell Therapeutics Corp. (BCT) has secured an exclusive licence from University of Maryland to develop and commercialize Soluble CD80 as a biologic agent for cancer treatment
  • The novel technology bears the title “Soluble CD80 as a Therapeutic to Reverse Immune Suppression in Cancer Patients”
  • It was originally developed by Suzanne Ostrand-Rosenberg
  • The terms of the agreement empower BriaCell to gain the worldwide rights to develop and commercialize sCD80, while UMBC maintains ownership of the patents
  • About BriaCell Therapeutics is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer
  • BriaCell Therapeutics Corp. was up 4.841 per cent, trading at $8.88 at 9:39 AM ET

BriaCell Therapeutics (BCT) has secured a licence from the University of Maryland, Baltimore County (UMBC).

The license allows BriaCell to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.

The novel technology bears the title “Soluble CD80 as a Therapeutic to Reverse Immune Suppression in Cancer Patients” and covered under USPN 8,956,619 B2, USPN 9,650,429 B2, and USPN 10,377,810 B2.

It was originally developed by Suzanne Ostrand-Rosenberg, Ph.D., Emeritus Faculty at UMBC, and member of BriaCell’s scientific advisory board.

In animal models, sCD80 was well tolerated and stopped tumour growth by potentially restoring natural anti-tumour immunity.

Additionally, strong anti-tumor activity of sCD80 has been reported in multiple tumor types.

The terms of the agreement allow BriaCell to gain the worldwide rights to develop and commercialize sCD80, while UMBC maintains ownership of the patents.

In return, BriaCell will pay royalties to UMBC upon the commercialization of the product plus patent management costs.

“Our mission has been to develop safe and effective treatments for cancer patients who do not respond to existing treatments, and a transformational anti-cancer agent such as sCD80 may provide us with such an additional opportunity,” stated Dr. Bill Williams, BriaCell’s President and CEO.

“Based on the promising data in animal studies, we plan to explore the potential use of sCD80 technology as a therapeutic agent in combination with our other immunotherapies or on its own.”

About BriaCell Therapeutics is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.

BriaCell Therapeutics Corp. was up 4.841 per cent, trading at $8.88 at 9:39 AM ET.


More From The Market Herald

" MCI Onehealth (TSX:DRDR) and Euclid Telehealth work to improve patient vision

MCI Onehealth (DRDR) and Euclid Telehealth are collaborating to increase access to care that can potentially prevent vision loss among Ontario patients.

" Spectral Medical (TSX:EDT) reports Q2 2022 results

Spectral Medical (EDT) released its financial results for the second quarter ended June 30, 2022.

" Hemostemix (TSXV:HEM) closes second tranche of non-brokered private placement

Hemostemix (HEM) has closed the second tranche of a non-brokered private placement of units for gross proceeds of $1,364,710.10.

" Nova Leap Health (TSXV:NLH) posts 2nd highest Q2 results in its history

Nova Leap Health (NLH) released its financial results for the quarter ended June 30, 2022.